{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=4-Part+Intervention&page=12", "query": { "intervention": "4-Part Intervention", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 745, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=4-Part+Intervention&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=4-Part+Intervention&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T04:07:46.586Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03030261", "title": "Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma in Relapse" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 25, "start_date": "2017-11-22", "completion_date": "2027-09-26", "has_results": true, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-11-01T04:07:46.586Z", "location_count": 2, "location_summary": "Denver, Colorado • St Louis, Missouri", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03030261" }, { "nct_id": "NCT06529731", "title": "Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Interferon gamma-1b", "type": "DRUG" }, { "name": "Donor Leukocyte Infusion (DLI)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sawa Ito, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2024-09-23", "completion_date": "2029-10-31", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-11-01T04:07:46.586Z", "location_count": 3, "location_summary": "St Louis, Missouri • Pittsburgh, Pennsylvania • Seattle, Washington", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06529731" }, { "nct_id": "NCT04341441", "title": "Will Hydroxychloroquine Impede or Prevent COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19", "Coronavirus", "Coronavirus Infections", "SARS-CoV 2" ], "interventions": [ { "name": "Hydroxychloroquine - Daily Dosing", "type": "DRUG" }, { "name": "Hydroxychloroquine - Weekly Dosing", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "OTHER" }, { "name": "Monitoring Visit - Baseline", "type": "DIAGNOSTIC_TEST" }, { "name": "Monitoring Visit - Week 4", "type": "DIAGNOSTIC_TEST" }, { "name": "Monitoring Visit - Week 8", "type": "DIAGNOSTIC_TEST" }, { "name": "Weekly Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 624, "start_date": "2020-04-07", "completion_date": "2020-12-15", "has_results": true, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-11-01T04:07:46.586Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04341441" }, { "nct_id": "NCT02314169", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Canal Squamous Cell Carcinoma", "Metastatic Anal Canal Carcinoma", "Stage IV Anal Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2015-05-13", "completion_date": "2027-03-20", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-11-01T04:07:46.586Z", "location_count": 55, "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 43 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Derby", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02314169" }, { "nct_id": "NCT04585789", "title": "A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "JNJ-73763989", "type": "DRUG" }, { "name": "JNJ-56136379", "type": "DRUG" }, { "name": "Entecavir (ETV)", "type": "DRUG" }, { "name": "Tenofovir disoproxil", "type": "DRUG" }, { "name": "Tenofovir alafenamide (TAF)", "type": "DRUG" }, { "name": "PegIFN-alpha-2a (Optional)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2021-03-11", "completion_date": "2024-01-09", "has_results": true, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-11-01T04:07:46.586Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04585789" }, { "nct_id": "NCT06555939", "title": "Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Collaborative Care Model", "type": "BEHAVIORAL" }, { "name": "Promoting Resilience in Stress Management", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "8 Years to 25 Years" }, "enrollment_count": 25, "start_date": "2025-10-23", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-11-01T04:07:46.586Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06555939" }, { "nct_id": "NCT02938377", "title": "Alcohol Research Consortium in HIV-Intervention Research Arm", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Positive", "Alcohol Use" ], "interventions": [ { "name": "Computerized Brief Intervention (CBI)", "type": "BEHAVIORAL" }, { "name": "CBT4CBT", "type": "BEHAVIORAL" }, { "name": "Recommendation and Counseling for Alcohol Pharmacotherapy", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4985, "start_date": "2017-11-06", "completion_date": "2023-11-01", "has_results": true, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-11-01T04:07:46.586Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Seattle, Washington", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02938377" }, { "nct_id": "NCT01614275", "title": "Using Web-based Technology to Expand and Enhance Applied Behavioral Analysis Programs for Children With Autism in Military Families", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Autism Spectrum Disorders" ], "interventions": [ { "name": "Technology-Enhanced Parent Training", "type": "BEHAVIORAL" }, { "name": "Technology-Enhanced Tutor Training", "type": "BEHAVIORAL" }, { "name": "Technology-enhanced Early Intensive Behavioral Intervention", "type": "BEHAVIORAL" }, { "name": "No-Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": "48 Months", "sex": "ALL", "summary": "18 Months to 48 Months" }, "enrollment_count": 66, "start_date": "2012-05-30", "completion_date": "2018-07-01", "has_results": false, "last_update_posted_date": "2018-02-07", "last_synced_at": "2026-11-01T04:07:46.586Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01614275" }, { "nct_id": "NCT04154631", "title": "Implementing and Sustaining a Sleep Treatment to Improve Community Mental Part 1: Implementation Health Outcomes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sleep Disorder", "Circadian Dysregulation" ], "interventions": [ { "name": "Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)", "type": "BEHAVIORAL" }, { "name": "Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)", "type": "BEHAVIORAL" }, { "name": "Usual Care Delayed Treatment", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "University of California, Berkeley", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 489, "start_date": "2020-01-08", "completion_date": "2023-12-19", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-11-01T04:07:46.586Z", "location_count": 10, "location_summary": "Concord, California • Fairfield, California • Goleta, California + 7 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Fairfield", "state": "California" }, { "city": "Goleta", "state": "California" }, { "city": "Hanford", "state": "California" }, { "city": "Lucerne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04154631" }, { "nct_id": "NCT06168812", "title": "A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer Metastatic", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Glipizide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2023-12-05", "completion_date": "2026-12-05", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-01T04:07:46.586Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06168812" } ] }